NCT07092527View on ClinicalTrials.gov

Androgen Effects on the Reproductive Neuroendocrine Axis, 2025 Version

PHASE4RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

November 15, 2028

Study Completion Date

November 30, 2028

Conditions
TransgenderismReproductive Issues
Interventions
DRUG

Testosterone Cypionate 50 milligrams per millileter (mg/mL) Injectable Solution

Participants in the initiating group will receive weekly doses of testosterone for gender-affirming care.

Trial Locations (1)

92037

RECRUITING

University of California, San Diego, San Diego

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

University of California, San Diego

OTHER